ERAS
Price
$14.50
Change
-$0.14 (-0.96%)
Updated
Nov 4, 03:15 PM (EDT)
Capitalization
5.12B
7 days until earnings call
Intraday BUY SELL Signals
GLUE
Price
$10.94
Change
+$0.53 (+5.09%)
Updated
Nov 4, 03:16 PM (EDT)
Capitalization
888.11M
One day until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ERAS vs GLUE

ERAS vs GLUE Comparison Chart in %
View a ticker or compare two or three
VS
ERAS vs. GLUE commentary
Nov 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Buy and GLUE is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ERAS with price predictions
Nov 03, 2026

ERAS's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ERAS turned positive on October 20, 2026. Looking at past instances where ERAS's MACD turned positive, the stock continued to rise in 52 of 55 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ERAS as a result. In 83 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.

Following a +5.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where ERAS advanced for three days, in 209 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

ERAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 58 cases where ERAS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ERAS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for ERAS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ERAS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.150) is normal, around the industry mean (3.051). P/E Ratio (-15.411) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for GLUE with price predictions
Nov 03, 2026

Momentum Indicator for GLUE turns negative, indicating new downward trend

GLUE saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned negative. In 82 of the 90 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLUE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

GLUE broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for GLUE entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GLUE's RSI Oscillator exited the oversold zone, 25 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for GLUE just turned positive on October 12, 2026. Looking at past instances where GLUE's MACD turned positive, the stock continued to rise in 43 of 47 cases over the following month. The odds of a continued upward trend are 90%.

Following a +1.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where GLUE advanced for three days, in 231 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.823) is normal, around the industry mean (3.051). P/E Ratio (-5.949) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (40.650) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. GLUE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLUE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

TECHNICAL ANALYSIS
Technical Analysis
ERASGLUE
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 9 days ago
83%
Bullish Trend 7 days ago
87%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Nov 04, 2026
Stock price -- (ERAS: $14.64 vs. GLUE: $10.41)
Brand notoriety: ERAS and GLUE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 87% vs. GLUE: 96%
Market capitalization -- ERAS: $5.12B vs. GLUE: $888.11M
ERAS [@Biotechnology] is valued at $5.12B. GLUE’s [@Biotechnology] market capitalization is $888.11M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $134.53B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green while GLUE’s FA Score has 1 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • GLUE’s FA Score: 1 green, 4 red.
According to our system of comparison, ERAS is a better buy in the long-term than GLUE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 4 TA indicator(s) are bullish while GLUE’s TA Score has 4 bullish TA indicator(s).

  • ERAS’s TA Score: 4 bullish, 3 bearish.
  • GLUE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than GLUE.

Price Growth

ERAS (@Biotechnology) experienced а -3.81% price change this week, while GLUE (@Biotechnology) price change was -2.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.61%. For the same industry, the average monthly price growth was -11.21%, and the average quarterly price growth was -16.43%.

Reported Earning Dates

ERAS is expected to report earnings on Nov 11, 2026.

GLUE is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-3.61% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with SNGX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then SNGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+4.20%
SNGX - ERAS
54%
Loosely correlated
-1.41%
REPL - ERAS
42%
Loosely correlated
+5.95%
AMLX - ERAS
39%
Loosely correlated
+4.14%
GLUE - ERAS
37%
Loosely correlated
-2.07%
RZLT - ERAS
36%
Loosely correlated
+3.35%
More

GLUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLUE has been loosely correlated with RVMD. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if GLUE jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLUE
1D Price
Change %
GLUE100%
-2.07%
RVMD - GLUE
44%
Loosely correlated
+3.22%
IPSC - GLUE
40%
Loosely correlated
+2.70%
NRIX - GLUE
40%
Loosely correlated
+0.47%
ARVN - GLUE
40%
Loosely correlated
-5.72%
KURA - GLUE
40%
Loosely correlated
+0.92%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ATI180.335.95
+3.41%
ATI
COCO59.691.48
+2.54%
Vita Coco Company (The)
EQS0.630.01
+1.05%
Equus Total Return
RGR45.120.29
+0.65%
Sturm Ruger & Company
DOUG1.58-0.02
-1.25%
Douglas Elliman